NCT02598557 - Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

December 6, 2016

Primary Completion Date

October 3, 2019

Study Completion Date

February 2, 2023

Conditions

Stage 0 Breast Cancer AJCC v6 and v7Stage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage II Breast Cancer AJCC v6 and v7Stage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7

Interventions

DRUG

Exemestane

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

OTHER

Placebo Administration

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (5)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

16128

Galliera Hospital, Genoa

20141

European Institute of Oncology, Milan

33612

Moffitt Cancer Center, Tampa

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH